By Michael McCaughan
More of everything. That is the succinct way to summarize The RPM Report's analysis of the second year of life...
The second year of the FDAAA-era is over, and FDA is using its new drug safety tools (Risk Evaluation & Mitigation Strategies and mandatory post-marketing studies) more often. Not only are more drugs requiring REMS and mandatory trials, the burden of those programs is increasing.
By Michael McCaughan
More of everything. That is the succinct way to summarize The RPM Report's analysis of the second year of life...